Beyond Microscopy: Pathology Informatics

7th March 2021


Digital Pathology, Computational Pathology & Artificial Intelligence ( 07:45 am to 10:15 am )

Time (IST)

Topic

Faculty

07:45 am - 08:00 am
Welcome
Session 1
08:00 am - 08:30 am
Advancing Pathology Diagnostics: Application of Digital Pathology and Artificial Intelligence
08:30 am - 09:00 am
How DP is transforming Pathology Academic Departments
09:00 am - 09:30 am
Coronation of Digital Pathology by Corona
Moderator of Panel discussion : Sujay Prasad
09:30 am - 10:00 am
Panel discussion : Digital Pathology - How do we do it right
10:00 am - 10:15 am
Concluding Remarks

Digital Pathology, Computational Pathology & Artificial Intelligence ( 03:45 pm to 05:45 pm )

Time (IST)

Topic

Faculty

03:45 pm - 04:00 pm
Welcome
Session 2
Moderator : Swapnil Rane
04:00 pm - 04:30 pm
Nuts and Bolts of DP
04:30 pm - 05:00 pm
Framing ethics in AI around the patient
05:00 pm - 05:30 pm
National Pathology Imaging Co-Operative (NPIC) - Expanding digital pathology collaboration from local to regional to national
05:30 pm - 05:45 pm
Concluding Remarks

Digital Pathology, Computational Pathology & Artificial Intelligence ( 05:45 pm am to 8:15 pm )

Time (IST)

Topic

Faculty

05:45 pm - 06:00 pm
Welcome
Session 3
06:00 pm - 06:30 pm
Computational Pathology and PathLake
06:30 pm - 07:00 pm
Pathomics for Precision Oncology
07:00 pm - 07:30 pm
Update on Clinical Validation Guidelines for WSI & AI in Pathology
07:30 pm - 08.00 pm
Emerging Challenges in the Application of Deep Learning to Cancer Image Analysis
08:00 pm - 8:15 pm
Concluding Remarks

Anant Madabhushi

Case Western Reserve University

Anant Madabhushi, PhD, is the Donnell Institute Professor of biomedical engineering at Case Western Reserve University (CWRU) in Cleveland and director of the university’s Center for Computational Imaging and Personalized Diagnostics (CCIPD). He is also a Research Scientist at the Louis Stokes Cleveland Veterans Administration (VA) Medical Center and has affiliate appointments both at University Hospitals and Cleveland Clinic. He holds secondary appointments in the departments of Biomedical Engineering, Urology, Radiology, Pathology, Radiation Oncology, Electrical Engineering & Computer Science and Gen Med Sciences at CWRU.

Madabhushi’s team at CCIPD is developing and applying novel Artificial Intelligence and machine learning approaches for the diagnosis, prognosis and prediction of therapy response for a variety of diseases including several different types of cancers, cardiovascular disease, kidney and eye disease. The Center is located in Cleveland’s unique medical ecosystem, an extensive clinical network within which it boasts numerous successful collaborations including with the Cleveland Clinic and the Cole Eye Institute, University Hospitals, the VA Louis Stokes Medical Center, MetroHealth, and the Case Comprehensive Cancer Center at CWRU.

Madabhushi has more than 100 patents either issued or pending in the areas of medical image analysis, computer-aided diagnosis, and computer vision, more than 50 of which are issued. He was responsible for more than 10 percent of all patents awarded to Case Western Reserve University in 2017, 2018 and 2019.

The author of more than 400 peer-reviewed journal articles and conference papers, Madabhushi is a sought after lecturer who has delivered more than 325 talks around the world. His efforts as a professor and researcher have gained international attention in the field of biomedical engineering, garnering him several awards. Most notably, Madabhushi is a fellow of the American Institute of Medical and Biomedical Engineering (AIMBE), a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a fellow of the National Academy of Inventors (NAI). In 2015, he made Crain’s Cleveland Business magazine’s “Forty under 40” list. In 2019 and 2020, Madabhushi was named to The Pathologist's Power List, a list of 100 most inspiring professionals in pathology and laboratory medicine. In 2020, he received the Diekhoff Award for Distinguished Graduate Student Mentoring at CWRU.

Madabhushi’s work on developing “smart computers for identifying lung cancer patients who will benefit from chemotherapy” was ranked as one of the top 10 medical breakthroughs of 2018 by Prevention Magazine. In 2019, Nature Magazine called him out as one of five scientists pursuing truly offbeat and innovative approaches in cancer research. His work on using AI for addressing health disparities, especially in identifying differences in appearance of prostate cancer between black and white men, received national attention in 2020.

Madabhushi has secured more than $60 million in grant funding and co-founded two companies, Vascuvis Inc. (now Elucid Bioimaging) and IbRiS Inc., which was acquired by Inspirata in 2015. He has been involved in several sponsored research and industry partnerships with medical imaging and pharmaceutical companies. In addition, more than 15 technologies developed by Madabhushi’s team have been licensed.

Mamta Yashawant Gurav

Scientific Officer, Tata Memorial Hospital

EDUCATIONAL QUALIFICATION: Masters in Biotechnology (2009) from Mumbai University

EXPERIENCE: Working as a Scientific Officer ‘Cin Molecular Pathology, Tata Memorial Hospitalsince January 2020.
Working as a Scientific Officer ‘SB’in Molecular Pathology, Tata Memorial Hospitalsince June 2013-December 2019.
Worked as a Scientific Officer ‘C’in Tumour Tissue Repository, Tata Memorial Hospitalfrom October 2012 to June 2013.
Workedas a Research Fellowin Tata Memorial Hospital from December 2010to September 2012.
Worked as a Research Assistantin National Institute for Research in Reproductive Health, Mumbai,from July 2009 to November 2010.



ACHIEVEMENTS:
  1. Recipient of International Trainee Travel Award 2019 for attending AMP Annual Meeting 2019 held from 6th-9thNovember 2019 at Baltimore, USA.
  2. Recipient of International membership grant 2017 of Association of Molecular Pathology (AMP)
  3. Awarded with International Molecular Pathology Conference Travel Award (2017) for attending 1stAMP Global Congress on Molecular Pathology held from 3rd-5thApril 2017 at Berlin, Germany.

Madhuri Hegde

PerkinElmer, Inc.

Dr. Hegde is the VP and Chief Scientific Officer, Global Laboratory Services. She joined PerkinElmer on October 1, 2016. The focus of her clinical work is the development and implementation of high-throughput next generation sequencing (NGS) strategies for genomic disorders using sequence capture technologies, robotics, clinical exome and genome sequencing, and oligonucleotide array platforms.

Dr. Hegde has over 20 years’ experience in clinical diagnostics which includes laboratory administration, management, extensive business and consulting experience in life science, genomic tools, and molecular diagnostic companies, from start-up to established organizations, and a proven record of driving revenue growth and profitability through growing existing businesses, building new businesses, and developing strategies to enter new markets by effectively influencing others to achieve shared goals.

Dr. Hegde has extensive knowledge of CLIA regulations related to LDTs and NGS and a strong understanding of current reimbursement landscape and new CPT coding guidelines. Most recently Dr. Hegde was with Emory Genetics Laboratory in Atlanta where she was Professor, Human Genetics and Pediatrics and Executive Director and Chief Scientific Officer of Emory Genetics Laboratory.

She received a B.Sc. and a M.Sc. from the University of Bombay, India, and a Ph.D. from the University of Auckland, New Zealand. She completed post-doctoral studies at Baylor College of Medicine and is American Board of Medical Genetics certified in Clinical Molecular Genetics.

Rajendra Singh

Northwell Health

Dr. Singh is a Professor in Dermatology and Pathology at Northwell Health, New York. He directs the Dermatopathology Section and is the Associate Chair of Digital Pathology. He is board certified in pathology and dermatopathology and board eligible for Clinical Informatics. He is the Founder of PathPresenter, an online digital platform that has 125,000+ users in 170+ countries and is used by multiple academic departments, private pathology groups and organizations in the US and all over the world. (https://pathpresenter.ai/) Dr. Singh has served on various committees both at the University of Pittsburgh and at Mt. Sinai as well as national societies such as the ASDP, AAD, DPA and CAP. Dr.Singh is the Recipient of the ‘Teacher of the Year Award’ at Mt. Sinai School of Medicine for 5 consecutive years. He has served as the Chair of the American Society of Dermatopathology Informatics Committee. He currently serves on the Sulzberger Grant Committee of the AAD and on the Editorial Board of JAAD. In 2013, he was awarded the Sulzberger Grant from the American Academy of Dermatology for developing interactive tools for teaching of dermatology and dermatopathology. He is the Editor, creator and developer of the app, mydermpath+ and educational platforms-wiydx.com. He also serves as a member of the Editorial Board of the WHO for Classification of tumors, 5th Edition and the Board of Digital Pathology Association.

Anita Grigoriadis

Kings College London

Anita Grigoriadis is a Reader in Cancer Bioinformatics and the Non-Clinical Deputy Head for the Breast Cancer Now Unit at King’s College London (KCL), London UK. After finishing her degree at the Institute of Molecular Pathology, University of Vienna (Austria), Anita pursued a joint PhD between the Ludwig Institute for Cancer Research (LICR), London UK and Faculty of Natural Sciences, Salzburg Austria. Anita conducted her postdoctoral training on breast cancer genomics at the LICR, and then worked with Professor Alan Ashworth at Breakthrough Breast Cancer Centre (London). In 2008, she joined the Breast Cancer NOW Unit (formerly Breakthrough Breast Cancer Research) at KCL under the leadership of Professor Andrew Tutt, and started her own team in 2013. In addition, Anita is the School Lead (International), the European Regional Network Lead for the College and the Training Lead for the CRUK KHP Centre and CRUK City of London postgraduate education.

Her research comprises the implementation of analytical approaches to integrate molecular, clinical and pathological data mainly in triple negative breast cancers. The Cancer Bioinformatics teams uses molecular techniques and digital pathology to (i) explore genomic alterations pathognomonic for DNA damage repair defects, (ii) to understand histological changes reflective of local and systemic immune responses, and (iii) how the sum of these individual components influences treatment response and disease progression.

Sangeeta Desai

Professor and Head, Pathology, Tata Memorial Centre

Dr. Sangeeta Desai is a Professor and Head, Pathology, Tata Memorial Centre. Her areas of interest are Surgical Pathology with special interest in Breast cancer, Urologic cancer, Telemedicine, Molecular diagnostics, Research bioethics and Biorepository science. She champions the cause of Telemedicine/Digital Pathology and Molecular diagnostics. She established a telelink for second opinion and primary diagnosis between rural cancer hospital in Barshi, Maharashtra and Tata Memorial Hospital, Mumbai, in the year 2000 and has been in the field of Molecular diagnostics since the year 2004. She has over 150 peer reviewed publications to her credit.

Liron Pantanowitz

University of Michigan

Dr. Liron Pantanowitz is a Professor in the Department of Pathology and the Director of Anatomical Pathology at the University of Michigan in Ann Arbor, MI, USA. He received his medical degree from the University of Witwatersrand in South Africa. He completed his anatomical and clinical pathology residency training at Beth Israel Deaconess Medical Center, Harvard in Boston. He subsequently completed a hematopathology fellowship at Harvard and Cytopathology fellowship at Tufts. He is also board certified by the American Board of Pathology in clinical informatics. Dr. Pantanowitz is an Editor-in-Chief of the Journal of Pathology Informatics. He is a past president and current council member of the Association of Pathology Informatics, president-elect of the American Society of Cytopathology, and a member of the Digital Pathology Association board of directors. He is widely published in the field of pathology informatics and cytopathology. His research interests include digital pathology and artificial intelligence.

Bethany Williams

National Pathology Imaging Co-Operative, Leeds Teaching Hospitals NHS Trust, United Kingdom

Dr Bethany Williams is a Digital Pathology Research Fellow at Leeds Teaching Hospitals NHS Trust and the University of Leeds, and the Lead for Training, Validation and PPI at the National Pathology Imaging Co-Operative. She is a thought leader in evidence based digital pathology training and validation, and her scientific papers on digital diagnostic accuracy form the basis of the Royal College of Pathologists’ guidelines for safe, effective digital deployment. Her body of research earned her the Pathological Society’s medal for research impact, and she is regularly invited to speak at international conferences as an authority on the digital pathology evidence base, practical deployment and patient safety.

Kirti Chadha

Metropolis Healthcare Ltd

Gold Medalist Pune University , Armed Forces Medical College
National training in Tata Memorial Hospital, Hinduja, Sir Ganga Ram and other COE
International Training in UK , Germany , USA (Memorial Sloan Kettering Cancer Centre)
Memberships and association – WHO , ICS , IAP ID, APPI , CAP

Current Designation :
Group Head & Senior VP – Medical Affairs, Oncomet & MedEngage

Omshree Shetty

Molecular Pathology Laboratory, Tata Memorial Hospital

She is a scientific officer at Molecular Diagnostics and Translational Medicines since half a decade. Her lab is a division of Pathology at Tata Memorial Hospital. Over these years, primarily focuses on developing and standardizing, validating essential molecular diagnostics to be used for personalized therapy.

As a Scientific officer working in the Molecular Diagnostics laboratory, the primary vision includes Patient care by providing accurate, reliable diagnosis and to accentuate the performance of the laboratory towards achieving this goal on everyday basis. This includes developing new molecular assays which addresses the following D; biomarker for diagnosis, P: predictive value for prognosis, C: indicator for chemo sensitivity/ MDR, T: potential target for treatment, which will be accomplished on next gen sequencer platform by designing comprehensive gene panels for various disease and to make available these facilities accessible to all.

As one of the leading molecular diagnostic centers for solid tumors in the country, She have initiated a quality assurance program for molecular Diagnostics Molecular Pathology Quality Assurance Program [MPQAP], this initiative is taken up with purpose to develop method based proficiency testing for developing uniformity while maintaining the Quality of the molecular diagnostics tests being performed and interpreted in this country in collaboration with NCG.

Swapnil Rane

Department of Pathology, Tata Memorial Centre

He is a pathologist at Tata Memorial Centre, Mumbai, having obtained his M.D. & D.N.B. during his residency program from PGIMER, Chandigarh. Dr. Rane obtained his post-doctoral specialist training in renal and transplant pathology from PGIMER, Chandigarh upto 2012 and in Oncopathology from Tata Memorial Centre, Mumbai from 2012 onwards. He also obtained a MRes degree from King’s College, London in 2014, after which he rejoined Tata Memorial Centre and is a faculty since 2015.

Dr. Rane is a computational, molecular and histo-pathologist and has been a signatory authority on molecular pathology reports since 2015. He has keen interest in bioinformatics and computational pathology in addition to conventional anatomic pathology and molecular pathology. He has advanced understanding of statistics, modelling techniques, as well as deep learning and has been using machine learning to make sense of biological and clinical information. Dr. Rane is an advanced user of statistical packages such as SPSS, Excel, power query, ACCESS, etc in addition to possessing coding skills in python and SQL. Dr. Rane has numerous collaborative projects in the field of histopathology image analysis with many collaborators from academia as well as industry. He is keen on transdisciplinary approaches to find answers to medical questions

Sujay Prasad

Anand Diagnostic Laboratory - A Neuberg Associate

Dr.Sujay Prasad, is the creative force behind new innovations, technology initiatives and business process improvements at Anand Diagnostic Laboratory, A Neuberg Associate. He has been instrumental in expanding the service capability of Anand Lab from facility expansion to acquisition of state of the art equipment. With his zero tolerance attitudes to errors, he has designed innovative methods that focus on minimizing errors across all operating processes. He oversees all IT initiatives and has implemented interesting IT enabled ideas such as automated report printing kiosks and online results reporting, much ahead of the industry adoption. He is also a certified lead assessor for NABL (ISO 15189 accreditation) and has conducted technical assessments overseas.

Dr. Prasad completed his graduation from M S Ramaiah Medical College, Bangalore and obtained his MD in Pathology from the Mumbai University. He joined Anand Diagnostic Laboratory in 1995.

His work has provided him experience in Hematology, Flow cytometry (non neoplastic diseases), Clinical Chemistry, Digital Pathology, Electrophoresis, Mass Spectrometry in Lab Medicine, Interface between Lab Medicine and Information Technology, Artificial intelligence in Lab Medicine.

Guest lectures on
Quality in Laboratory Medicine.
Digital Pathology in routine practice Hemoglobin Variants and their detection methods.
Mass spectrometry in Immunosuppressant’s and Vitamin D
Errors in Laboratory Medicine
Cost of Cutting Cost In Laboratory Medicine
Hematology Seminars
Laboratory Information System Workshop and Seminar on Electrophoresis in Myeloma.
Artificial Intelligence in Laboratory Medicine
Mindfulness in Laboratory Medicine
Sigma Metric as a risk management tool

Marc Ladanyi

Memorial Sloan Kettering Cancer Center

Dr. Marc Ladanyi (MD) is Attending Pathologist and Chief of the Molecular Diagnostics Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. As Chief of Molecular Diagnostics Service at MSKCC, he oversees large scale prospective clinical genotyping efforts based on a variety of next-generation sequencing technologies which is part of a center-wide precision medicine strategy. His research laboratory studies the genomics and therapeutic targets of lung adenocarcinoma, mesothelioma, and several types of sarcoma. Dr. Ladanyi received his medical degree from McGill University in Montreal.

Dhananjay Chitale

Henry Ford Health System

Dr.Chitale is the Systemwide Vice-Chair of Anatomic Pathology,Division Head ofMolecular Pathology and Genomic Medicine, Medical Director of theHFCI Tissue Biorepository& Immunohistochemistry research core, Senior Staff Surgical Pathologistwith subspecialtylead pathologist on the Breast, Molecular, Muskuculoskeletal Tumor Boardsat Henry Ford Health System and Associate Clinical ProfessoratWayne State University School of Medicine. He has been namedas Hour Detroit’s Top Doc list for last fiveconsecutive years(2016-2020) based on a peer-review survey of approximately 23,000 physicians in metropolitan Detroit.

Dr. Chitale received his medical degree from University of Mumbai, Mumbai, India (SethG.S. Medical College and King Edward Memorial Hospital, Mumbai India). He completed his residency training and board certification in Pathology from Tata Memorial Hospital, University of Mumbai, Mumbai India. He then completed hissecond residency training in Anatomic and Clinical Pathology at Henry Ford Hospital, Detroit, MI. Following which Dr.Chitale completed his fellowship training in Oncologic Surgical pathology and Molecular pathology at Memorial Sloan-Kettering Cancer Center, New York, NY. He completed post-doctoral training (Research Associate in Thoracic oncology, 2006-2007) at Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Chitale is currently pursuing his Masters in Business Administration at the Ross School of Business at the Univesity of Michigan, Ann Arbor

He is a board certified Pathologistwith board certifications in Molecular Genetic Pathology (American Board of Pathology (ABP) and American Board of Medical Genetics (ABMG)), Molecular diagnostics (American Board of Clinical Chemistry), Anatomic and Clinical pathology (ABP), Diplomate of National Board in Pathology, New Delhi, India, Board certification in Pathology,MD Pathology,University of Mumbai, India.

Dr.Chitale is widely published with 81coauthored peer reviewed publications, 6book chapters, 5 books and over 138published abstract presentations in the form of posters and oral presentations at various national and international meetings.He has lectured locally, nationally and internationallyas invited speaker. Dr. Chitale has provided Service for Peer-Reviewed Journals as a Reviewerof Manuscriptsfor eight high impact journals.He has been a co-author on the Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors:Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Dr. Chitale has mentored 40resident trainee, fellows and PhD candidates and was awarded best teacher of the year in Anatomic Pathology 2years in a row. Dr.Chitale's collaborative research has beenfunded through various organizations including Susan G.Komen Breast Cancer foundation, National Institute of Health (NIH),National Cancer Institute (NCI), Department of Defence (DoD)with focusonepigenetic alterations in ER negative breast cancers, molecular alterations in breast cancer in patients with neurofibromatosis, the Study of Breast Cancer Subtypes, A Nested Case-Control Study of Prostate Carcinogenesis.

Houtan Noushmehr

Henry Ford Health System

My academic training and research experience have provided me exposure to many different areas of science including human physiology & diseases, molecular biology, genetics and bioinformatics & biostatistics. During my doctoral training, I gained new insight and understanding of epigenetic changes associated with Glioblastoma, a primary brain tumor by applying my bioinformatic skills. Not only did this work lay the foundation for my scientific curiosity in the field of epigenetics (specifically DNA methylation), but also fulfilled an exciting collaborative experience. I have participated in a number of analysis working groups within The Cancer Genome Atlas (TCGA), and led several brain cancer initiative to classify and evaluate the prognostication of DNA methylation, including a project that characterized the stemness signatures across 33 tumor types spanning more than 10,000 samples using DNA methylation and Expression. As a professor and researcher I manage a team of bioinformatician. My goals are to advance our understanding of the genomics and epigenomics that define normal and disease states specifically cancer and to create a bioinformatic workflow to analyze and interpret genomic and epigenomic data from patient biopsies in order to offer guided therapy. Recently, we have embarked on applying epigenetics to detect glioma in serum cell-free DNA as an approach to non-invasively monitor tumor progression.

Rajiv Kumar

Department of Pathology, Tata Memorial Centre

Dr. Rajiv Kumar is a Professor in the Department of Pathology, Tata Memorial Hospital (THM) Mumbai, India. He received his medical degree from Grant Medical College, Mumbai and completed his residency training in pathology at TMH, Mumbai. Subsequently he joined PGIMER, Chandigarh and worked there for three years. In March 2012, he joined TMH as Assistant Professor in the department of pathology. He had special interest in Thoracic, Gastrointestinal Oncopathology, molecular pathology and digital pathology. MAYO Clinics have awarded him Geraldine C. Zeiler fellowship to participate in Mayo clinic visiting clinician Program at Scottsdale, Arizona, USA for training in pulmonary pathology. He is a recipient of the Terry fox research Grant. In addition to routine diagnostic work, he looks after the administrative responsibility of establishing the Digital Pathology network across various centers of TMC. He had many publications in national and international journals to his credit.

Michael Feldman

University of Pennsylvania

Personal Statement: My professional interests revolve around the development of institutional biobanking as well as the integration and adoption of information technologies in the discipline of Pathology, to that end, we have partnered with Pittsburgh and NYU on the national mesothelioma virtual tissue banking project, the largest mesothelioma biosample bank in the world. My work in the field of tissue banking included being an early funded adopter and tester in the NCI caBIG project, we partnered on testing of caTissue with University of Pittsburgh and were the first cancer center using both caTissue and caTIES. caTIES has now morphed into a multicenter Tissue Collaborative Research Network (TCRN) which is NIH funded and which is being extended in this application.

In the field of digital imaging, I have been developing computer assisted diagnostic algorithms for machine vision in breast cancer (Collaboration with Dr. Anant Madhabushi Case Western) and quantitative scoring of immunohistochemical and immunofluorescent stains of FFPE tissue. Our newest area of investigation is the use of Imaging mass cytometry of pancreas tissues and multispectral imaging for the analysis of multicolor immunohistochemistry and immunoflourescence and the development of a quantitative system for scoring and analyzing at a cytometric level, multicolor immunostaining on surgical pathology slides which was recently used in multiple of breast cancer publications listed below. The efforts have been recognized by the national funding agencies from the NIH, Synergy award from DOD as well as an industry sponsored projects.

Nasir Rajpoot

University of Warwick

Professor of Computational Pathology &
Director, Tissue Image Analytics (TIA) Lab
University of Warwick, UK

Honorary Pathology Scientist, UHCW NHS Trust, Coventry, UK
Turing Fellow, The Alan Turing Institute, London, UK
Wolfson Fellow, The Royal Society, UK
Co-Director, PathLAKE CoE, UK

Homepage: http://www.warwick.ac.uk/nmrajpoot
Lab Pages: http://www.warwick.ac.uk/TIAlab

Nasir Rajpoot is Professor of Computational Pathology at the Computer Science department of the University of Warwick, where he started his academic career as a Lecturer (Assistant Professor) in 2001. He also holds an Honorary Scientist position at the Department of Pathology, University Hospitals Coventry & Warwickshire NHS Trust since 2016.
Prof Rajpoot is the founding Head of Tissue Image Analytics laboratory (TIA lab) at Warwick since 2012. In Autumn 2017, he was awarded the Wolfson Fellowship by the UK Royal Society and the Turing Fellowship by the Alan Turing Institute, the UK’s national institute for data science and artificial intelligence.
Current focus of research in Prof Rajpoot’s lab is on developing algorithms for the analysis of digitised pathology images, with applications to computer-assisted grading of cancer and image-based markers for prediction of cancer progression and survival. He has been active in the digital pathology community for almost a decade now, having co-chaired several meetings in the histology image analysis (HIMA) series since 2008 and served as a founding PC member of the SPIE Digital Pathology meeting since 2012.
Prof Rajpoot served as the President of the European Congress on Digital Pathology (ECDP), which was held at Warwick in April 2019. Since Jan 2019, he acts as Co-Director of the £15m PathLAKE national centre of excellence on AI in pathology, leading the computational arm of the centre.

Anguraj Sadanandam

The Institute of Cancer Research

Dr Sadanandam is a Reader and Team Leader (tenured Associate Professor) at the Institute of Cancer Research (ICR), London since 2013. He is currently applying his multidisciplinary skills to integrated science of stratified medicine to understand inter-and intra-tumoural/immuneheterogeneity and test precise therapies for different subtypes of cancers using computational (artificial intelligence), experimental (including pre-clinical in vitroand in vivomodels) and clinical (accessing clinical trial samplesby developing companion diagnostics) biology. After, obtaining his PhD from USA, Dr. Sadanandam completed his postdoctoral fellowship with two world-renowned mentors: Joe Gray(USA)and Douglas Hanahan(Switzerland). He briefly worked at Swiss Institute of Cancer.

Dr. Sadanandam led the research work to define transcriptome/multi-omicssubtypes of colorectal, gastroesophageal, breast and multiple pancreatic cancers associated with prognosis and potential personalised medicine (multiple high-impact Nature Medicine, Cancer Cell, Cancer Discovery, Cell, Science and otherpublicationsout of more than 60 publications). These subtypes and classifications are highly cited and applied by the research and clinical community. He is a major contributor in multiple consortia including ColoRectal Cancer Subtyping Consortium (CRCSC; Guinney et al., Nature Medicine 2015) and clinical trials.

Dr. Sadanandam is a Founder ofa Centre for Global Oncology at the ICRand currentlyco-ordinating multiple projects related to Global (specifically Low-MiddleIncome Countries including India) Cancer Research.

He is one of the Advisors of Indian Cancer Genome Atlas (ICGA) project. He has won several awards and honours. He is internationally known for his subtyping and personalised cancer research. He has Honorary Appointments at Royal Marsden Hospital, UK and Mayo Clinic, USA. Previously, he did his postdoctoral trainings with Professors Joe Gray and Douglas Hanahan.

Mandar Ankolkar

Scientific Officer, Tata Memorial Hospital

Educational Qualification:
Dr. Mandar Ankolkar (Ph.D) is from Mumbai, India. He completed his PhD in Life Sciences in 2013 from National Institute for Research in Reproductive Health [NIRRH] (affiliated to Mumbai University) on deciphering the male epigenetic factors involved in recurrent spontaneous miscarriages. His graduation (B.Sc) and post-graduation (M.Sc) is in Biotechnology from Mumbai University. He has completed his ICMR funded Post Doctoral research on ‘The effect of Hormonal modulation on the nucleosomal localization in rat sperm chromatin’ from NIRRH.

Current affiliation:
He is currently affiliated as Scientific Officer in the Molecular Pathology Division (Department of Pathology) at Tata Memorial Hospital since 2018. Area of expertise: His area of expertise is Molecular Biology and he has good knowledge and experience in various molecular biology techniques including PCR, DNA Sanger Sequencing, Next Generation Sequencing (NGS), Multiplexed Ligation dependent Probe Amplification (MLPA), Fluorescent In situ hybridization (FISH), DNA methylation studies, bioinformatics, Realtime PCR.

Publications:

He has got many publications in reputed international journals in diverse fields of research.
(https://pubmed.ncbi.nlm.nih.gov/?term=Mandar+Ankolkar&sort=date)
1.Into the Unknown-exploring a Rare BRAF K601E Mutation in a Rectal Adenocarcinoma. Karnik, N., Ankolkar, M., Gogte, P., Ramadwar, M., Ostwal, V., & Shetty, O. (2020). Journal of Advances in Medicine and Medical Research, 32(24), 224-228.
2. Florid lymphoid hyperplasia in breast: Waxing and Waning process. Rao S, Shet T, Shetty D, Jain H, Ankolkar M, Joshi S.Breast J. 2020 Nov;26(11):2252-2254.
3. Systemic hormonal modulation induces sperm nucleosomal imbalance in rat spermatozoa. Ankolkar M, Deshpande SS, Balasinor NH.Andrologia. 2018 Oct;50(8):e13060.
4. Endocrine control of epigenetic mechanisms in male reproduction. Ankolkar M, Balasinor NH.Horm Mol Biol Clin Investig. 2016 Jan;25(1):65-70.
5. Aberrant methylation of multiple imprinted genes in embryos of tamoxifen-treated male rats. Kedia-Mokashi NA, Kadam L, Ankolkar M, Dumasia K, Balasinor NH.Reproduction. 2013 Jul 3;146(2):155-68.
6. Methylation status of imprinted genes DLK1-GTL2, MEST (PEG1), ZAC (PLAGL1), and LINE-1 elements in spermatozoa of normozoospermic men, unlike H19 imprinting control regions, is not associated with idiopathic recurrent spontaneous miscarriages. Ankolkar M, Salvi V, Warke H, Vundinti BR, Balasinor NH.Fertil Steril. 2013 May;99(6):1668-73.
7. Methylation analysis of idiopathic recurrent spontaneous miscarriage cases reveals aberrant imprinting at H19 ICR in normozoospermic individuals. Ankolkar M, Patil A, Warke H, Salvi V, Kedia Mokashi N, Pathak S, Balasinor NH.Fertil Steril. 2012 Nov;98(5):1186-92.
8. Potential role of estrogen in regulation of the insulin-like growth factor2-H19 locus in the rat testis. Pathak S, D'Souza R, Ankolkar M, Gaonkar R, Balasinor NH.Mol Cell Endocrinol. 2010 Jan 15;314(1):110-7.
Awards and achievements:
He received the ICMR Post Doctoral Research Fellowship in 2016.
He received the Young Investigator poster award in the Association of Molecular Pathology (AMP Global) meeting in Hong Kong in 2019.
Certifications:
Certified for completing Good Clinical Practice (GCP) conducted by NIDA clinical trials network, NIH, Bethesda, USA.

Amit Sethi

IIT Bombay

Amit Sethi is an Associate Professor of Electrical Engineering at the Indian Institute of Technology Bombay and an Adjunct Instructor of Pathology at University of Illinois at Chicago. His research interests lie in machine learning and deep learning and their applications to images, particularly to cancer pathology. He obtained his post-secondary education at Indian Institute of Technology Delhi and University of Illinois at Urbana-Champaign. He has previously worked at NEC Labs America in Cupertino CA, ZS Associates in Chicago, and Indian Institute of Technology Guwahati.

Giorgia RiboldiTunnicliffe

SOPHiA GENETICS

Giorgia R Riboldi-Tunnicliffe is the APAC Subject Matter Experts Manager from SOPHiA GENETICS. She comes to SOPHiA GENETICS with over 20 years’ experience in sequencing. After her PhD in Jena (Germany), she managed the University of Glasgow Sequencing and Microarray facility for 5 years. She has later on worked in the support teams of the two major NGS players (Thermo Fisher and Illumina). Before joining SOPHiA GENETICS, she’s been applying her knowledge as marketing expert in the South APAC region for Reproductive Genetic Health.

Juan Retamero

Philips Digital and Computational Pathology

Dr Juan Antonio Retamero is an anatomical pathologist with extensive experience in the implementation and use of digital pathology for routine diagnosis. He played a key role in the adoption of digital pathology in a pioneering group of hospitals in Spain in 2016. Since then, he has shared his experiences worldwide and has supported many centers in the adoption of digital pathology, including labs in the United States and many countries in Europe and Asia. He is a regular speaker at different digital and computational events globally and is an ardent advocate for the modernization of the profession.

Gauri Deshpande

Department of Pathology, Tata Memorial Centre

• Consultant pathologist at Tata Memorial Center, Mumbai
• MD Pathology and Fellowship in molecular pathology at TMC, Mumbai
• Actively involved in validation and reporting of various molecular pathology assays, including next generation sequencing
• Special interests: Gastrointestinal tumours
• Research involving medulloblastoma gene expression profiling

Trupti Pai

Department of Pathology, Tata Memorial Centre

Dr Trupti Pai is a Consultant Pathologist at Tata Memorial Centre (TMC), Mumbai. She completed her MD Pathology from TMC, HBNI University, Mumbai followed by one year of senior residency in Oncopathology and 2 years of fellowship in Molecular pathology from TMC. She then was selected for the one year fellowship in Translational Cancer Medicine and obtained the MRes degree from the Kings College London. Subsequently, she joined as a faculty in the Pathology Department at TMC, Mumbai in October 2017.

Her areas of interest are Thoracic Oncopathology and Molecular Pathology. She is actively involved in the validation and reporting of all solid tumour molecular assays, including next generation sequencing (NGS) based tests. Her research areas of interest include tumour microenvironment, HER2 Genomic heterogeneity and Biomarker assessment in lung tumours. She has over 25 peer-reviewed publications in the national and international journals to her credit.

Subhash Yadav

Department of Pathology, Tata Memorial Centre

Dr. Subhash Yadav is an Associate Professor in the Department of Pathology at Tata Memorial Hospital, Mumbai since 2018. He has completed his MD in Pathology from Seth G.S Medical College and KEM Hospital, Mumbai. Subsequently, he did his senior residency in Oncopathology at Tata Memorial Hospital, Mumbai. He was Assistant Professor at Seth G.S Medical College and KEM Hospital, Mumbai before joining Tata Memorial Hospital in 2016. He has special interest in Thoracic pathology, digital and computational pathology. He is actively involved in developing the “Synoptic Reporting System” for pathology reports for TMH and also across various centers of TMC. In addition to routine surgical pathology work, he is also involved in maintenance of the Synoptic Reporting System and Digital Pathology System.

Anil Parwani

The Ohio State university

Dr. Anil Vasdev Parwani, M.D., Ph.D., MBA, is a Chair in Pathology, The Donald A. Senhauser, M.D. Endowment, The Ohio State University, USA. He serves as the Vice Chair and Director of Anatomic Pathology, Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH. Dr. Parwani is also the Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at The James Cancer Hospital. Dr. Parwani has expertise in Urologic pathology and Anatomic Pathology Informatics including designing quality assurance tools, clinical and research data integration, applications of whole slide imaging, digital imaging, telepathology, image analysis, lab automation and bio banking informatics. Dr. Parwani is the Editor-in-chief of Diagnostic Pathology and Journal of Pathology Informatics. He is a member and adorns leadership positions in several professional and scientific societies viz. Association of Pathology Informatics, College of American Pathologists (Digital Pathology Committee Member), USCAP, Digital Pathology Association, American Association for Cancer Research etc. He is a recipient of several awards including Association for Pathology Informatics Distinguished Service Award in the year 2018 in recognition of his outstanding contributions to the development and evolution of informatics as integral element of pathology education and practice and tireless efforts in the establishment and editorial guidance of the Journal of Pathology Informatics. He is a prolific researcher and speaker. His publications include 323 peer reviewed publications, 13 books, 46 book chapters and 7 invited editorials, in addition to 431 published abstracts and several conference proceedings.

Subhash Yadav

Department of Pathology, Tata Memorial Centre

Dr. Subhash Yadav is an Associate Professor in the Department of Pathology at Tata Memorial Hospital, Mumbai since 2018. He has completed his MD in Pathology from Seth G.S Medical College and KEM Hospital, Mumbai. Subsequently, he did his senior residency in Oncopathology at Tata Memorial Hospital, Mumbai. He was Assistant Professor at Seth G.S Medical College and KEM Hospital, Mumbai before joining Tata Memorial Hospital in 2016. He has special interest in Thoracic pathology, digital and computational pathology. He is actively involved in developing the “Synoptic Reporting System” for pathology reports for TMH and also across various centers of TMC. In addition to routine surgical pathology work, he is also involved in maintenance of the Synoptic Reporting System and Digital Pathology System.

David Jaffray

Vice President & Chief Technology and Digital Officer University of Texas MD Anderson Cancer Center
(TMC Hospital Day Orator)

Dr. David Jaffray is a senior vice president and chief technology and digital officer (CTDO) at The University of Texas MD Anderson Cancer Center. He also is professor of Radiation Physics with a dual appointment as professor of Imaging Physics.

Recruited to MD Anderson in May 2019, Dr. Jaffray is the institution’s inaugural chief technology and digital officer (CTDO), bringing more than two decades of scientific expertise and proven skill as an innovator. In this role, he directs the strategic design, acquisition, management and implementation of an enterprise-wide technology infrastructure at MD Anderson to safeguard the integrity and availability of the institution’s systems and intellectual property assets.

Before joining MD Anderson, Dr. Jaffray served as executive vice president for Technology and Innovation at the University Health Network (UHN)/Princess Margaret Cancer Centre in Toronto, Ontario. He led UHN’s information technology transformation, designed the roadmap for digital transformation. He also served in several other leadership roles at UHN, including vice chair of Research for the University of Toronto's Department of Radiation Oncology, founding director of the STTARR Innovation Centre, and founding director of the Techna Institute for the Advancement of Technology for Health. As the Head of Medical Physics, he led the technological transformation of the Princess Margaret’s Radiation Medicine Program to a world leader in RT.

Dr. Jaffray held an academic appointment as a Full Professor in the Departments of Radiation Oncology, Medical Biophysics, and IBBME at the University of Toronto. He was active in strategic planning, teaching, and graduate student supervision during his 17 years in Toronto.

Dr. Jaffray holds multiple patents and has authored more than 275 peer-reviewed publications in topics related to cancer, including, the development of new radiation treatment machines, exploring the fundamental limits of imaging system performance, and the development of novel nanoparticle formulations for improved detection of cancer.

During the course of his career, he has received many honors, including the Sylvia Sorkin-Greenfield Award, the Farrington Daniels Award and the Sylvia Fedoruk Award. In 2018, he received the Gold Medal from the American Society for Radiation Oncology. Dr. Jaffray has an interest in commercialization and has led the development of a variety of commercial products, including software and hardware for safe, high-quality cancer care and the development of numerous radiation therapy technologies, including the development of cone-beam CT guided radiation therapy.

Michael Feldman

University of Pennsylvania

Personal Statement: My professional interests revolve around the development of institutional biobanking as well as the integration and adoption of information technologies in the discipline of Pathology, to that end, we have partnered with Pittsburgh and NYU on the national mesothelioma virtual tissue banking project, the largest mesothelioma biosample bank in the world. My work in the field of tissue banking included being an early funded adopter and tester in the NCI caBIG project, we partnered on testing of caTissue with University of Pittsburgh and were the first cancer center using both caTissue and caTIES. caTIES has now morphed into a multicenter Tissue Collaborative Research Network (TCRN) which is NIH funded and which is being extended in this application. In the field of digital imaging, I have been developing computer assisted diagnostic algorithms for machine vision in breast cancer (Collaboration with Dr. Anant Madhabushi Case Western) and quantitative scoring of immunohistochemical and immunofluorescent stains of FFPE tissue. Our newest area of investigation is the use of Imaging mass cytometry of pancreas tissues and multispectral imaging for the analysis of multicolor immunohistochemistry and immunoflourescence and the development of a quantitative system for scoring and analyzing at a cytometric level, multicolor immunostaining on surgical pathology slides which was recently used in multiple of breast cancer publications listed below. The efforts have been recognized by the national funding agencies from the NIH, Synergy award from DOD as well as an industry sponsored projects.

Andre Dekker

Maastrict University

Prof. Andre Dekker, PhD (1974) is a medical physicist and professor of Clinical Data Science at Maastricht University Medical Center and Maastro Clinic in The Netherlands. His Clinical Data Science research group (30 staff) focuses on 1) federated FAIR data infrastructures, 2) AI for health outcome prediction models and 3) applying AI to improve lives of patients and citizens. Prof. Dekker has authored over 170 publications (h-index 55+), mentored more than 30 PhD students and holds multiple awards and patents on the topic of federated data and AI. He has held visiting scientist appointments at universities and companies in the UK, Australia, Italy, USA and Canada.

Ajay Aggarwal

London School of Hygiene and Tropical Medicine

Dr Ajay Aggarwal is a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust, London and Associate Professor at the London School of Hygiene and Tropical Medicine. His main research areas are Health Services Research and Global Health and he is the current editor of the Journal of Cancer Policy. He has been the recipient of two fellowship awards from the National Institute for Health Research (NIHR) in 2014 and 2020. In his role as the Oncology Coordinator for the UK National Prostate Cancer Audit, he co-led the development and delivery of the first ever national public outcome reporting programme for radiotherapy. He also leads a comparative effectiveness research programme for prostate cancer using «real world evidence ». His research has contributed significantly to national and international policy discussion around the affordability of cancer care and the value of new technologies in cancer medicine which has influenced directly both WHO Cancer Drug Pricing and Benefits Taskforces, and the European Medicines Agency. As co-chair of the Health Economics in Radiation Oncology (HERO) group within ESTRO (European Society for Radiation Oncology), he is co-leading the value-based health care initiative and working with the European Commission to support reimbursement policy for medical devices in cancer care. He has previously worked at the World Health Organisation in Geneva, and has ongoing global health projects in South Africa, Botswana and Ghana aimed at building radiotherapy capacity and cancer research capability.

Bishal Gyawali

Orthopaedic Oncology, Prince of Wales Hospital, the Chinese University of Hong Kong

Bishal Gyawali, MD, PhD is a medical oncologist from Nepal who has trained and worked in various countries including Nepal, Japan, U.S and Canada. He is currently working as an assistant professor in the Department of Public Health Sciences, scientist in the Division of Cancer Care and Epidemiology, a clinical fellow in the Department of Medical Oncology at Queen’s University, Kingston, Canada and an affiliated faculty at the Program On Regulation, Therapeutics and Law in the Department of Medicine at Brigham and Women's Hospital, Boston, USA. He is a member of the WHO Essential Medicine List for Cancer Drugs, ESMO-Magnitude of Clinical Benefit Scale and ESMO-MCBS Quality of Life working groups. He is also currently serving as a research consultant to the Nepal Health Research Council and has previously served as a medical consultant for the not-for-profit Anticancer Fund, Belgium. He is in the editorial and advisory board for multiple medicine and oncology journals including Cell, JCO Global Oncology, JCO Oncology Practice and ecancer, has authored or co-authored a hundred peer-reviewed articles and is the recipient of the 2020 ASCO Conquer Cancer Foundation Global Oncology Young Investigator Award in Implementation Science. He was also awarded by the Government of Nepal with Young Health Researcher Award in 2020. His areas of academic interests include cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care. He is an advocate of "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. Dr. Gyawali tweets at @oncology_bg.

Shankar Prinja

Post Graduate Institute of Medical Education and Research, Chandigarh, India

Dr. Shankar Prinja is an Additional Professor of Health Economics at the PGIMER School of Public Health, Chandigarh, India. Starting off as a medical doctor and public health specialist, he went on to do health economics from the London School of Economics. His main research interests involve economic evaluation of health care interventions and programs, costing of health care services, and analyzing impact of health financing policies in the context of universal health coverage. He is a member of several high level technical expert groups including the subgroups of Prime Minister’s Economic Advisory Council on “Investment in Human Resources and Infrastructure” as well as “Converging Health Care and Social Security Financing Platforms”, Technical Appraisal Committee for Health Technology Assessment Board; Vaccine Cost Effectiveness Analysis Working Group of the NTAGI (National Technical Advisory Group on Immunization), ICMR’s COVID-19 Taskforce on Operations Research, and Research Advisory Council of the Public Health Foundation of India. At the PGI School of Public Health, he has set up a Regional Resource Centre for India’s Health Technology Assessment Board, as well as an Innovation and Learning Centre for Health and Wellness Centres in Punjab. He has authored more than 185 research papers in leading national and international peer-reviewed scientific journals. He is also an Academic Editor of the PLoS One, member of the editorial board of Pharmacoeconomics Open, and guest editor of the Indian Journal of Medical Research.

Swapnil Rane

Department of Pathology, Tata Memorial Centre

He is a pathologist at Tata Memorial Centre, Mumbai, having obtained his M.D. & D.N.B. during his residency program from PGIMER, Chandigarh. Dr. Rane obtained his post-doctoral specialist training in renal and transplant pathology from PGIMER, Chandigarh upto 2012 and in Oncopathology from Tata Memorial Centre, Mumbai from 2012 onwards. He also obtained a MRes degree from King’s College, London in 2014, after which he rejoined Tata Memorial Centre and is a faculty since 2015.

Dr. Rane is a computational, molecular and histo-pathologist and has been a signatory authority on molecular pathology reports since 2015. He has keen interest in bioinformatics and computational pathology in addition to conventional anatomic pathology and molecular pathology. He has advanced understanding of statistics, modelling techniques, as well as deep learning and has been using machine learning to make sense of biological and clinical information. Dr. Rane is an advanced user of statistical packages such as SPSS, Excel, power query, ACCESS, etc in addition to possessing coding skills in python and SQL. Dr. Rane has numerous collaborative projects in the field of histopathology image analysis with many collaborators from academia as well as industry. He is keen on transdisciplinary approaches to find answers to medical questions

Aliasgar V Moiyadi

Officer In-charge, Clinical Research Secretariat & DAE-CTC
Professor and Head, Neuro Surgery, Division of Surgical Oncology, Tata Memorial Centre

Dr. Aliasgar V Moiyadi is Professor & Consultant Neurosurgeon, Chief of Neurosurgery, Tata Memorial Centre. He is the Officer-in-Charge, Clinical Research Secretariat, Tata Memorial Hospital, Mumbai. He is in the Executive Committee of Indian Society of Neuro-oncology. He is a Section Editor in World Neurosurgery. He is a Member and Technology Committee at World Federation of Neurosurgical Societies. He has many peer-reviewed journal articles, abstracts and book chapters on various topics including thoracic oncology, clinical research methods, translational research and cancer policy. He has strong interests in clinical trial designs, surgical trials, comparative effectiveness research, promoting collaborative research and cancer policy.

C S Pramesh

Director, Tata Memorial Hospital
Professor and Head, Thoracic Surgery, Division of Surgical Oncology, Tata Memorial Centre

Dr C S Pramesh is the Director of the Tata Memorial Hospital and the Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai. He serves on the UICC Board of Directors. He is the convener for the National Cancer Grid, a large network of 236 cancer centres in India (https://tmc.gov.in/ncg). The mandate of the National Cancer Grid is to provide uniform standards of cancer care across the country. He is highly committed to efforts towards reducing inequities in cancer care and making cancer treatment accessible to all geographic regions and strata of society. He is also a visiting professor at the Division of Cancer Studies, King’s College London and the Institute of Cancer Policy, King’s Health Partners, London.

His clinical interests include the management of esophageal and lung cancers and minimally invasive surgery. He is the Secretary of the Indian Society for Diseases of the Esophagus and Stomach (ISES). He is the Principal Investigator in several investigator-initiated research studies including randomized trials on cancer screening, surgical techniques, neoadjuvant and adjuvant treatment of thoracic cancers. He has more than 200 peer-reviewed journal articles, abstracts and book chapters on various topics including thoracic oncology, clinical research methods, translational research and cancer policy.

He has strong interests in clinical trial designs, surgical trials, comparative effectiveness research, promoting collaborative research and cancer policy. He has completed the Post Graduate Diploma in Clinical Trials offered by the London School of Hygiene and Tropical Medicine, University of London. He is keen on promoting training in clinical research methods and conducts several courses on clinical research methodology, biostatistics and scientific writing. He serves on the advisory boards of several national and international research organizations and granting agencies.